Ceryvyn Therapeutics (ASX:CYV) swung to a A$330 million profit in FY26, driven by a one-off gain from settling a major funding agreement. The company pivots to rare lung disease drug development with a lean cash runway.
- FY26 profit of A$330 million after prior year loss of A$251 million
- Gain of A$357 million from derecognition of Development Funding Agreement liability
- Pivot to CYV-101 inhaled therapy targeting rare lung disease LAM
- A$30 million cash on hand, no debt, stage-gated clinical development planned
- Company rebranded from Opthea to Ceryvyn Therapeutics reflecting new strategy
Massive profit turnaround driven by funding deal settlement
Ceryvyn Therapeutics Limited (ASX:CYV), formerly Opthea, reported a dramatic financial turnaround for the year ended 30 June 2026, posting a profit after tax of A$330 million compared to a loss of A$251 million the previous year. This swing was almost entirely due to a one-off accounting gain of A$357 million following the derecognition of a Development Funding Agreement (DFA) liability settled in August 2025.
The DFA settlement extinguished a substantial financial obligation, restoring the company’s solvency and providing a much-needed boost to its balance sheet. At year-end, Ceryvyn held A$30 million in cash and cash equivalents with no debt, and net tangible assets per share improved from negative 24.93 cents to positive 2.16 cents.
Strategic pivot to rare lung disease with existing biologic asset
Following the DFA settlement, the Board conducted a comprehensive strategic review, concluding that the best path forward was to redeploy the company’s existing biologic asset, CYV-101, into a new therapeutic area rather than acquiring new assets or returning capital to shareholders.
CYV-101 is a first-in-class fusion protein designed to neutralise VEGF-C and VEGF-D, key drivers of lymphatic dysfunction. Ceryvyn is developing an inhaled formulation aimed at treating lymphangioleiomyomatosis (LAM), a rare, progressive lung disease predominantly affecting women. LAM currently has no cure and limited treatment options, making it an attractive orphan disease target.
The company’s pivot leverages years of prior investment; approximately US$120 million (A$179 million) in manufacturing infrastructure and clinical data from late-stage ophthalmology trials; providing a strong foundation for efficient development. The Board emphasises a disciplined, stage-gated approach with predefined scientific and capital milestones, ensuring investment is tied to clear evidence rather than optimism.
Governance and operational streamlining under new leadership
In line with its new focus, Ceryvyn restructured its Board and management team. Jeremy Levin, with extensive pharmaceutical leadership experience including at Teva and Bristol Myers Squibb, assumed combined roles as Executive Chair and CEO during this transition. The company also appointed a Scientific Advisory Board featuring experts in LAM and rare diseases to guide development.
The company formally changed its name from Opthea Limited to Ceryvyn Therapeutics Limited in July 2026 to reflect its strategic refocus on rare diseases. It also voluntarily delisted its American Depository Shares from NASDAQ in late 2025, consolidating its operations and reporting in Australian dollars following the cessation of US-based activities.
Financial discipline amid ongoing R&D investment
Ceryvyn reported total research and development expenses of A$2.2 million for FY26, a sharp reduction from the prior year’s A$193.8 million, reflecting the wind-down of previous ophthalmology programs and a leaner cost base. Administrative expenses also fell to A$9.7 million.
The company’s cash burn remains modest relative to its cash reserves, and it expects existing funds to support the initial proof-of-concept studies for CYV-101 in LAM through to late 2027. However, as a clinical-stage biotech with no approved products or revenue, Ceryvyn acknowledges the inherent risks and uncertainties of drug development, including regulatory approval, clinical success, and potential future capital needs.
Share-based payments remain a significant component of remuneration for directors and key management, aligning interests with long-term shareholder value creation. The company granted 130 million options during the year under its Long-Term Incentive Plan and Non-Executive Director Plan.
Outlook hinges on clinical milestones in rare disease space
Ceryvyn’s future now rests on its ability to execute the clinical development of CYV-101 in LAM, a rare disease with a small but well-defined patient population and established biomarkers. The company aims to demonstrate target engagement and safety with its inhaled formulation, potentially complementing existing treatments that target different pathways.
Success in this program could unlock orphan drug incentives and faster regulatory pathways, but the company remains clear-eyed about the scientific and operational risks ahead. With a streamlined cost structure, a solid cash position, and a focused strategy, Ceryvyn is positioning itself as a nimble player in the rare diseases biotech sector.
Investors should watch for upcoming clinical trial initiations, regulatory interactions, and data readouts that will provide early signals on CYV-101’s potential to address a significant unmet medical need.
Bottom Line?
Ceryvyn’s FY26 profit masks a one-off accounting gain, spotlighting a strategic reset toward rare lung disease; clinical milestones will be the true test.
Questions in the middle?
- Will CYV-101’s inhaled formulation demonstrate meaningful clinical benefit in LAM patients?
- How will Ceryvyn fund later-stage development if initial milestones are met but additional capital is required?
- Can the company leverage orphan drug incentives and biomarker-driven trial design to accelerate regulatory approval?